Downregulation of FBXO2 is associated with Aβ aggregation, tau hyperphosphorylation and network impairment in human cortical neurons
This study identifies FBXO2 as a critical transcriptomic regulator in sporadic Alzheimer's disease, demonstrating that its downregulation drives Aβ aggregation, tau hyperphosphorylation, and network impairment in human cortical neurons while revealing associated mitochondrial dysfunction.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Alzheimer's disease is the most common cause of dementia, a condition that slowly erodes memory and thinking skills. While some cases run in families due to a single, powerful genetic mutation, the vast majority of cases are sporadic, meaning they arise from a complex mix of many small genetic risks and environmental factors like diet or stress. Because these sporadic cases do not have a single clear cause, creating accurate models of the disease in a laboratory has been incredibly difficult. Scientists have struggled to build human cell models that capture the full, messy reality of the disease, where different problems happen at the same time. To solve this, researchers are now looking at the genetic instructions inside brain cells to find which ones change as the disease begins. By understanding these early shifts, they hope to find ways to nudge healthy cells into a disease-like state in the lab, allowing them to study the problem and test treatments without needing to wait for the disease to develop naturally in a person.
In a new study, a team of scientists at the University of Cambridge developed a systematic way to find these early warning signs. They started by analyzing genetic data from the brains of people who had passed away, comparing those with no signs of Alzheimer's to those in the early and late stages of the disease. They focused specifically on the prefrontal cortex, a region of the brain critical for thinking and decision-making. Instead of just looking for genes that were turned up or down, they examined how groups of genes worked together in networks. They identified specific pathways, or sets of instructions, that became distorted as the disease progressed. Three main areas stood out: how cells move materials inside themselves, how they break down waste, and how they send signals to one another. From these disrupted networks, the researchers picked thirty-five candidate genes that seemed most likely to be involved in the early stages of the disease.
To test if these genes were truly important, the team first used a simple model made of human neuroblastoma cells. They temporarily silenced each of the thirty-five genes, one by one, and then added a protein fragment known to clump together in Alzheimer's brains. They watched to see if silencing a gene made these clumps form faster or in greater numbers. Nine of the genes, when turned down, caused a significant increase in these clumps. Among the top results was a gene called FBXO2. When the researchers reduced the levels of FBXO2, the cells produced more than three times the amount of large protein clumps compared to normal cells. This gene is known to help the cell identify and dispose of misfolded proteins, so reducing it seemed to clog the cell's waste disposal system, allowing harmful proteins to build up.
The team then moved to a more sophisticated and realistic model: human neurons grown from stem cells. They used two types of these cells. One type carried a known genetic mutation that causes early-onset Alzheimer's, while the other type had a completely normal genetic background. They reduced the levels of FBXO2 in both types of neurons during their early development. In the neurons with the Alzheimer's mutation, the reduction of FBXO2 led to a clear increase in the secretion of toxic protein clumps and a rise in the accumulation of these clumps inside the nerve fibers. It also caused the nerve fibers to become thinner and less complex. Crucially, the same reduction in FBXO2 also triggered similar problems in the healthy neurons that had no genetic risk factors. These healthy cells began to produce more toxic protein clumps and showed signs of another hallmark of the disease: a specific type of chemical tagging on a protein called tau, which is known to become harmful in Alzheimer's.
The researchers also measured how well these neurons communicated with each other. Neurons in the brain work together in networks, firing electrical signals in bursts to transmit information. When FBXO2 levels were lowered, the neurons fired less frequently and their bursts of activity became less synchronized. This functional impairment happened even in the healthy neurons, suggesting that the loss of this single gene could push a normal brain cell toward a diseased state. To make the model even more realistic, the team added a liquid environment derived from astrocytes, a type of support cell in the brain. When the neurons were grown in this astrocyte-rich environment, the negative effects of reducing FBXO2 became even stronger. The neurons produced more toxic clumps and showed even greater signs of stress.
Finally, the team looked at the genetic instructions inside these stressed neurons to understand what was happening at a molecular level. They found that when FBXO2 was reduced in the presence of astrocyte signals, the cells showed signs of mitochondrial dysfunction. Mitochondria are the tiny power plants inside cells that generate energy. The genetic data suggested that these power plants were not working efficiently, which is a common feature seen in the brains of people with Alzheimer's. However, the researchers noted that these genetic changes were not always present at every stage of the experiment, suggesting that the damage caused by losing FBXO2 might happen through mechanisms that do not immediately show up in the genetic code, perhaps by affecting how proteins are handled after they are made.
The study does not claim that losing FBXO2 is the sole cause of Alzheimer's disease. Instead, it demonstrates that this gene acts as a critical switch for neuronal health. When its levels drop, human neurons become more vulnerable to the toxic protein clumps and signaling errors that define the disease. The findings suggest that the early stages of sporadic Alzheimer's might involve a gradual weakening of these protective mechanisms, making the brain more susceptible to damage. By identifying FBXO2 as a key player, the researchers have provided a new tool for studying the disease. They can now use these gene-altered cells to test how different treatments might restore the balance and prevent the cascade of damage that leads to dementia. This approach offers a promising path forward for understanding a disease that has long been too complex to model accurately.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.